MedTrace Logo

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

NCT04850625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2022-07-05

No results posted yet for this study

Summary

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Biyun Wang, Professor · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2021-06-15
Completion
2021-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850625 on ClinicalTrials.gov